ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,272 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentZugAlnylam Switzerland GmbH
Alnylam Switzerland GmbH Logo
Verified· 2 sources

Alnylam Switzerland GmbH

Summary

About the company

The company is a pharmaceutical or biotechnology company specializing in the development and manufacture of medicines for rare diseases. The core activity includes research and development of RNAi-based therapies, the manufacture and marketing of medicines, as well as the provision of patient services, including genetic counseling and patient advocacy.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered7
RNAi Medicines
RNAi medicines for rare and serious diseases, including AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO, using a gene-silencing mechanism.
Patient Support
Personalized support for patients during treatment, including help with insurance coverage, financial support options, educational materials and resources.
Genetic Testing and Counseling
No-charge genetic testing and counseling for people with suspected hATTR amyloidosis, acute hepatic porphyria or primary hyperoxaluria type 1.
Early Access to Investigational Medicines
Early access and compassionate-use access to selected investigational medicines for seriously ill patients when clinical trials or other treatment options are not available.
Clinical Trials
Alnylam-sponsored clinical trials evaluating the safety and effectiveness of new RNAi therapies for diseases with high unmet need.
RNAi Research and Drug Development
Research on RNA interference, delivery platforms and medicines development, including scientific work on therapeutic areas, pipeline and medicine manufacturing.
Information and Resources for Medical Professionals
Resources for medical professionals, including genetic testing and counseling, early access, medical publication support and investigator-initiated studies.
Comparisons

Alnylam Switzerland GmbH in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Alnylam Switzerland GmbH by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Alnylam Switzerland GmbH to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Grafenauweg 4
6300 Zug

At a glance

Legal form
Limited Liability Company
UID
CHE-312.245.389
Founded
2015 · 11 years
Last commercial register change
July 8, 2026
Employees
21 to 50

Knowledge

No knowledge articles yet

Once Alnylam Switzerland GmbH has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

AI
Apellis International GmbH
Zug
JP
Jazz Pharmaceuticals Switzerland GmbH
Zug
ME
Meditrial Europe AG
Zug
NT
Nektar Therapeutics Europe GmbH
Zug
RP
Rhythm Pharmaceuticals Switzerland GmbH
Zug
DP
Deciphera Pharmaceuticals (Schweiz) AG
Zug
PR
Premier Research Group SA
Zug
CP
Crinetics Pharmaceuticals Europe GmbH
Zug